key: cord-0989333-por0q7de
authors: McCartney, Patricia Robin
title: Sex-Based Vaccine Response in the Context of COVID-19
date: 2020-08-05
journal: J Obstet Gynecol Neonatal Nurs
DOI: 10.1016/j.jogn.2020.08.001
sha: dfdbd7b14224491eecf80b182cb9127890408b50
doc_id: 989333
cord_uid: por0q7de

nan

this disease, many states in the United States do not report or analyze differences in outcomes 11 between men and women. In some cases, when differences in outcomes are reported by sex, 12 findings are inconsistent . Data that are disaggregated for sex are necessary to 13 compare outcomes, inform clinicians, and enable appropriate risk assessment and care, including and adults reported greater pain than male children and adults. In this review, researchers in 57 prospective trials designed to actively solicit AE data identified sex-related differences. Cook 58 suggested that these differences may be related to immunity and subcutaneous and muscle tissue. potential need to tailor vaccines by age; sex differences were not discussed. A key concern 82 among all participants was hesitancy regarding vaccine uptake. reactions were mild or moderate, and no serious adverse reactions were reported. The data on 98 immunogenicity and AEs were not disaggregated for sex, and participants will be followed for 99 one year. In a trial of the adenovirus-vector vaccine candidate Ad5, Bar-Zeev and Moss (2020) 100 analyzed for sex differences and found that more women experienced fever as an AE. 

Encouraging results from phase 1/2 COVID-19 vaccine trials

Advance online publication

Clinical trials for COVID-19 should include sex as a 139 variable

Sex differences in injection site reactions with human vaccines

A strategic approach to COVID-144 19 vaccine R&D

Sex and gender impact immune responses to vaccines among 147 the elderly

The evolution of greater humoral immunity in females than 150 males: implications for vaccine efficacy

Sex differences in 153 vaccine-induced humoral immunity

Sex and gender differences in 156 the outcomes of vaccination over the life course

EDITORIAL COVID-19 VACCINES

Safety and immunogenicity of the

ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, 162 single-blind, randomised controlled trial. The Lancet

COVID-19 sex-disaggregated data tracker

Gender differences in immediate hypersensitivity reactions 167 to vaccines: A review of the literature

… 170 mRNA-1273 Study Group

Preliminary report

Biological sex impacts COVID-19 outcomes

Sex differences in immune responses

Accelerating COVID-19 Therapeutic Interventions and 179

Office of Research on Women's Health (n.d.). NIH policy on sex as a biological variable

Aggregating data from COVID-19 trials

The Salzburg statement on vaccination acceptance

Considering 191 how biological sex impacts immune responses and COVID-19 outcomes

Guidance for industry toxicity grading scale for 194 healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials

Regulations, guidance, and reports related to 197 women's health

Pathway to a vaccine: Efforts to 200 develop a safe, effective, and accessible COVID-19 vaccine

Draft landscape of COVID-19 candidate vaccines